THE INVESTIGATION OF SPECIFIC ANTIBODIES INTERACTION WITH CD44 PROTEIN

Anton Popov1, 2, Gabija Agasarjanaite2, Neda Zenkeviciute2, Viktorija Lisyte2, Asta Kausaite-Minkstimiene1, 2, Almira Ramanaviciene1, 2

1 Department of Immunology, Centre for Innovative Medicine, Vilnius, Lithuania

2 NanoTechnas – Center of Nanotechnology and Materials Science, Faculty of Chemistry and Geosciences, Vilnius University, Vilnius, Lithuania

The World Health Organization (WHO) estimated that in 2019 cancer was the 1st or 2nd leading cause of death under the age of 70 years in 112 of 183 countries. Furthermore, in 2020, more than 19 million new cancer cases were diagnosed and almost 10 million cancer deaths were recorded [1]. Diagnosing cancer in the early stages increases the likelihood of effective treatment and prolongation of the patient's life [2]. Transmembrane glycoprotein - CD44 (P-glycoprotein 1) is a cell surface adhesion receptor, which is highly expressed in many cancers. CD44 also controls metastasis by the expression to the cell surface [3]. Moreover, due to clinicopathological impacts and its isoforms in promoting tumorigenesis CD44 can be considered as a possible molecular target for cancer therapy [4]. The concentrations of cancer biomarkers in the human body in the early stages are quite low. Moreover, matrix effects caused by various species, which are present in body fluids, complicates the detection of biomarkers and normally requires sample dilution prior to testing [5]. Therefore, every opportunity should be taken to increase the sensitivity of immunosensors. One way of doing this is to select antibody that are best suited for immunosensors fabrication. Surface plasmon resonance (SPR) method is traditionally used for evaluation antibody-antigen interaction. Moreover, the calculation of immunoreaction kinetic parameters can be performed by analyzing of SPR results.

The main aim of this work was to investigate the interaction of CD44 protein with specific antibodies. The optimization of interaction conditions was performed. Moreover, the regeneration solution needed for multiple use of SPR sensor was chosen. Few types of specific antibodies against CD44 protein were selected for this work. The kinetics of antibody-antigen interaction were evaluated. Finally, the most suitable for fabrication of immunosensor specific antibodies against CD44 protein was chosen.

Acknowledgments: This project has received funding from European Social Fund (project no. 09.3.3-LMT-K-712-19-0170) under grant agreement with the Research Council of Lithuania (LMTLT).


[1] H. Sung, J. Ferlay, R. L. Siegel et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 71(3), 209-249 (2021).

[2] K. Whitaker, Earlier diagnosis: the importance of cancer symptoms, Lancet Oncol. 21, 6–8 (2020).

[3] L. T. Senbanjo, M. A. Chellaiah, CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells, Front. Cell Dev. Biol. 5, (2017).

[4] C. Chen, S. Zhao, A. Karnad et al., The biology and role of CD44 in cancer progression: therapeutic implications, J Hematol Oncol 11, 64 (2018).

[5] A. Ramanaviciene, A. Popov, E. Baliunaite et al., Magneto-immunoassay for the detection and quantification of human growth hormone. Biosens. 12, 65 (2022).